PSORIASIS Is ustekinumab superior to etanercept for psoriasis?

被引：6

作者：

Kuhn, Annegret ^{[1
]}

Luger, Thomas A. ^{[1
]}

机构：

[1] Univ Munster, Dept Dermatol, D-48149 Munster, Germany

来源：

NATURE REVIEWS RHEUMATOLOGY | 2010年 / 6卷 / 09期

关键词：

INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; TNF INHIBITION; TRIAL; EFFICACY; SAFETY;

D O I：

10.1038/nrrheum.2010.134

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Both etanercept and ustekinumab have been shown to be strikingly effective in patients with psoriasis. A phase III trial comparing these two biologic agents for the treatment of moderate-to-severe psoriasis found that ustekinumab was superior to high-dose etanercept over a 12-week period; however, several questions remain to be addressed.

引用

页码：500 / 501

页数：3

共 50 条

[31] Clinical experience of ustekinumab in the treatment of erythrodermic psoriasis: A case series
Wang, Ting-Shun
Tsai, Tsen-Fang
JOURNAL OF DERMATOLOGY, 2011, 38 (11): : 1096 - 1099
[32] Ustekinumab: moving the target from psoriasis to Crohn's disease
Settesoldi, Alessia
Coppola, Manuela
Rogai, Francesca
Annese, Vito
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (01) : 5 - 13
[33] Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)
Bagel, Jerry
Nia, John
Hashim, Peter W.
Patekar, Manmath
de Vera, Ana
Hugot, Sophie
Sheng, Kuan
Xia, Summer
Gilloteau, Isabelle
Muscianisi, Elisa
Blauvelt, Andrew
Lebwohl, Mark
DERMATOLOGY AND THERAPY, 2018, 8 (04) : 571 - 579
[34] Update on Ustekinumab for Psoriasis
Nia J.K.
Hashim P.W.
Kimmel G.
Aleisa A.
Farahani A.C.
Lebwohl M.G.
Current Dermatology Reports, 2017, 6 (1) : 29 - 34
[35] Etanercept: An Evolving Role in Psoriasis and Psoriatic Arthritis
Prodanovich, Srdjan
Ricotti, Carlos
Glick, Brad P.
Inverardi, Luca
Leonardi, Craig L.
Kerdel, Francisco
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2010, 11 : 3 - 9
[36] Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis
Meng, Y.
Dongmei, L.
Yanbin, P.
Jinju, F.
Meile, T.
Binzhu, L.
Xiao, H.
Ping, T.
Jianmin, L.
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2014, 39 (06) : 696 - 707
[37] Differential Response of Chronic Plaque Psoriasis to Briakinumab vs. Ustekinumab
Inzinger, Martin
Weger, Wolfgang
Salmhofer, Wolfgang
Wolf, Peter
ACTA DERMATO-VENEREOLOGICA, 2012, 92 (04) : 357 - 358
[38] Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Papp, Kim
Gottlieb, Alice B.
Naldi, Luigi
Pariser, David
Ho, Vincent
Goyal, Kavitha
Fakharzadeh, Steven
Chevrier, Marc
Calabro, Stephen
Langholff, Wayne
Krueger, Gerald
JOURNAL OF DRUGS IN DERMATOLOGY, 2015, 14 (07) : 58 - 66
[39] Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study
Patsatsi, Aikaterini
Kyriakou, Aikaterini
Sotiriadis, Dimitrios
JOURNAL OF DERMATOLOGICAL TREATMENT, 2013, 24 (02) : 96 - 100
[40] Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies
Santos-Juanes, J.
Coto-Segura, P.
Mas-Vidal, A.
Osuna, C. Galache
BRITISH JOURNAL OF DERMATOLOGY, 2010, 162 (05) : 1144 - 1146

← 1 2 3 4 5 →